News | April 08, 2022
Cadila Pharma launches world’s first three-dose rabies vaccine
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
It is currently available in tablet and injectable dosage forms
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
The symposium was organized by the Gut Microbiota and Probiotic Science Foundation (India) and Medanta Institute of Education and Research, Gurugram, and Amity University, Gurugram
Supply increase to help meet growing global demand
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
Subscribe To Our Newsletter & Stay Updated
